ClinicalTrials.gg
CompletedNCT00418522Updated Aug 11, 2026Results posted

This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

A Phase 4 interventional study of Insulin glargine and Inhaled Insulin (Exubera) in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 73 sites in 2 countries. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
413
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.

Enrollment
7th of 54
413 · median 60
Started
2007
with 1 other
Phase 4
20 of 54
2 open now
Registered
9th of 54
by date
Lead sponsor
3 of 54
Pfizer

Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 2 that started in 2007, is one of 20 in phase 4, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing insulin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study is to determine if inhaled insulin is effective in treating type 2 diabetes mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Insulin Glargine Diabetes HbA1c
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 30 years and ≤ 75 years with a diagnosis of type 2 diabetes mellitus made > 6 months prior to study entry
  • Screening > 7.0%
  • Currently treated on a stable dose of at least 2 oral antidiabetic agents for at least 3 months prior to study entry; including a sulfonylurea and/or metformin, and/or a thiazolidinedione

Exclusion criteria

Exclusion Criteria:

Smoking within last 6 months PFTs outside of range

  • Type 1 diabetes mellitus
  • Type 2 diabetes mellitus currently (last three months) treated with an insulin regimen (alone or with Oral Antidiabetic Agents)
  • Active liver disease; significantly-impaired hepatic function, as shown by, but not limited to, (ALT) serum glutamic pyruvic transaminase (SGPT) or aspartate transaminase (AST) serum glutamic-oxaloacetic transaminase (SGOT) above 2x the as measured at visit 1. However, patients with elevated ALT >1.5 upper limit of normal as a result of hepatic steatosis are permitted to enter the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
413 participants (actual)

Study arms

  • Active comparator
    Insulin glargine

    Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

    Drug: Insulin glargine

  • Experimental
    Exubera

    Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

    Drug: Inhaled Insulin (Exubera)

Interventions

  • Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

  • Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population

    HbA1c lab value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Percentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 26

    Percentage of subjects with glycosylated hemoglobin A1c lab value less than 6.5%.

    Time frame: Week 26

  2. Percentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 26

    Percentage of subjects with glycosylated hemoglobin A1c lab value less than 7.0%.

    Time frame: Week 26

  3. Percentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 26

    Number of subjects with glycosylated hemoglobin A1c lab value less than 8.0%.

    Time frame: Week 26

  4. Change From Baseline in Fasting Plasma Glucose at Week 26

    Fasting plasma glucose lab value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  5. Change From Baseline in Fasting and Postprandial Blood Glucose as Determined by Standardized Meal Tolerance Tests at Week 26

    Postprandial blood glucose lab value (Time 0 min \[fasting\], Time 30 min, Time 60 min, Time 90 min, Time 120 min, Time 180 min): Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  6. Change From Baseline in Postprandial Blood Glucose as Measured by 8-Point Profiles at Week 26

    Post-prandial=after a meal. 8-point scale: (1 = before breakfast, 2 = 2 hours post breakfast, 3 = before lunch, 4 = 2 hours post lunch, 5 = before dinner, 6 = 2 hours post dinner, 7 = at bedtime, 8 = overnight \[between 2 and 4 am\]). Postprandial blood glucose lab value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  7. Change From Baseline in Lipids at Week 26

    Lipid (total cholesterol, high density lipoprotein cholesterol \[HDL-c\], low density lipoprotein cholesterol \[LDL-c\], triglycerides) lab value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  8. Change From Baseline in Cardiovascular (CV) Biomarkers High Sensitivity C-reactive Protein (Hs-CRP), Leptin, and Spot Urine Microalbumin at Week 26

    CV biomarker (hs-CRP, Leptin, and Spot Urine Microalbumin) lab value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  9. Change From Baseline in CV Biomarkers Adiponectin and Apolipoprotein B (ApoB) at Week 26

    CV biomarker (adiponectin and ApoB) lab value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  10. Change From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26

    24-Hour CGMS glucose lab value was obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  11. Change From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26

    SD of 24-Hour CGMS glucose lab value obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  12. Number of Subjects With Hypoglycemic Events

    A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.

    Time frame: Months 1 to 7

  13. Number of Total Hypoglycemic Events

    A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe. Total=events during the study.

    Time frame: Months 1 to 7

  14. Number of Total Subject Months of Treatment

    Number of total subject months of treatment. Subject months = number of days from start of treatment to the last day of active treatment + 1 day lag, including off-drug time)/30.44. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.

    Time frame: Months 1 to 7

  15. Crude Hypoglycemic Event Rate

    crude event rate=(events)/(subject-months). Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.

    Time frame: Months 1 to 7

  16. Number of Nocturnal Hypoglycemic Events

    A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Nocturnal hypoglycemia=event occuring from midnight to 5:59 am.

    Time frame: Months 1 to 7

  17. Change From Baseline in Body Weight at Week 26

    Body weight value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

  18. Change From Baseline in Body Mass Index (BMI) at Week 26

    BMI value (kg/m2): Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

Other outcomes

  1. Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS

    HbA1c lab value: Change = value at Week 26 minus value at Baseline.

    Time frame: Baseline, Week 26

07

Results

Posted Sep 4, 2009
Limitations and caveats
Due to cancellation of the EXUBERA program, the Patient Reported Outcome (PRO) data were not collected, and no statistical analyses were performed.

Participant flow

Participant flow — Overall Study
MilestoneInhaled Human InsulinInsulin Glargine
Started219194
Received treatment212190
Completed136152
Not completed8342
Withdrew: Adverse event71
Withdrew: Lack of efficacy13
Withdrew: Lost to follow-up104
Withdrew: Withdrawal by subject317
Withdrew: Other2723
Withdrew: Randomized but did not receive treatment74

Outcome measures

PrimaryChange From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population

HbA1c lab value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · percent
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population
percentInhaled Human InsulinInsulin Glargine
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population-2.01 ± 1.39-1.75 ± 1.40
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = <0.0001 · Mean difference (final values): -0.19 · 95% CI -0.38 to 0A confidence interval (CI) approach was presented with a two-sided 95% CI of the difference between treatment and control.
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.0516 · Mean difference (final values): -0.19 · 95% CI -0.38 to 0The superiority test used a one-sided 2.5% level of significance.
SecondaryPercentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 26

Percentage of subjects with glycosylated hemoglobin A1c lab value less than 6.5%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 26
percentage of participantsInhaled Human InsulinInsulin Glargine
Percentage of Subjects Achieving Glycemic Control (HbA1c < 6.5%) at Week 2635.522.2
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · Regression, Logistic · p = 0.0052 · Odds ratio (or): 1.96 · 95% CI 1.22 to 3.14
SecondaryPercentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 26

Percentage of subjects with glycosylated hemoglobin A1c lab value less than 7.0%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 26
percentage of participantsInhaled Human InsulinInsulin Glargine
Percentage of Subjects Achieving Glycemic Control (HbA1c < 7.0%) at Week 2662.647.6
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · Regression, Logistic · p = 0.0022 · Odds ratio (or): 2.01 · 95% CI 1.29 to 3.15
SecondaryPercentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 26

Number of subjects with glycosylated hemoglobin A1c lab value less than 8.0%.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 26
percentage of participantsInhaled Human InsulinInsulin Glargine
Percentage of Subjects Achieving Glycemic Control (HbA1c < 8.0%) at Week 2679.883.6
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · Regression, Logistic · p = 0.2480 · Odds ratio (or): 0.71 · 95% CI 0.40 to 1.27
SecondaryChange From Baseline in Fasting Plasma Glucose at Week 26

Fasting plasma glucose lab value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose at Week 26
mg/dLInhaled Human InsulinInsulin Glargine
Change From Baseline in Fasting Plasma Glucose at Week 26-52.77 ± 69.48-53.50 ± 62.92
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.6091 · Mean difference (final values): 2.57 · 95% CI -7.31 to 12.46
SecondaryChange From Baseline in Fasting and Postprandial Blood Glucose as Determined by Standardized Meal Tolerance Tests at Week 26

Postprandial blood glucose lab value (Time 0 min \[fasting\], Time 30 min, Time 60 min, Time 90 min, Time 120 min, Time 180 min): Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/dL
Change From Baseline in Fasting and Postprandial Blood Glucose as Determined by Standardized Meal Tolerance Tests at Week 26
mg/dLInhaled Human InsulinInsulin Glargine
Time 0 at Week 26-35.22 ± 51.12-61.16 ± 54.68
Time 30 at Week 26-49.91 ± 62.41-66.02 ± 62.32
Time 60 at Week 26-56.83 ± 69.81-64.77 ± 64.47
Time 90 at Week 26-64.94 ± 75.67-58.85 ± 64.58
Time 120 at Week 26-66.59 ± 74.69-54.89 ± 63.02
Time 180 at Week 26-66.99 ± 74.19-51.27 ± 59.92
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = <0.0001 · Mean difference (final values): 32.96 · 95% CI 22.66 to 43.25
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = <0.0001 · Mean difference (final values): 28.57 · 95% CI 16.55 to 40.59
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.0044 · Mean difference (final values): 18.96 · 95% CI 5.96 to 31.96
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.3168 · Mean difference (final values): 6.69 · 95% CI -6.45 to 19.83
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.9222 · Mean difference (final values): 0.63 · 95% CI -12.12 to 13.39
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.6950 · Mean difference (final values): -2.41 · 95% CI -14.51 to 9.69
SecondaryChange From Baseline in Postprandial Blood Glucose as Measured by 8-Point Profiles at Week 26

Post-prandial=after a meal. 8-point scale: (1 = before breakfast, 2 = 2 hours post breakfast, 3 = before lunch, 4 = 2 hours post lunch, 5 = before dinner, 6 = 2 hours post dinner, 7 = at bedtime, 8 = overnight \[between 2 and 4 am\]). Postprandial blood glucose lab value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/dL
Change From Baseline in Postprandial Blood Glucose as Measured by 8-Point Profiles at Week 26
mg/dLInhaled Human InsulinInsulin Glargine
Post-Breakfast, Week 26-86.61 ± 85.98-75.36 ± 79.04
Post-Lunch, Week 26-86.66 ± 77.49-58.51 ± 86.93
Post-Dinner, Week 26-81.86 ± 75.94-59.20 ± 86.21
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.1207 · Mean difference (final values): -9.61 · 95% CI -21.76 to 2.54
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = <0.0001 · Mean difference (final values): -29.11 · 95% CI -39.77 to -18.44
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = <0.0001 · Mean difference (final values): -33.76 · 95% CI -44.17 to -23.35
SecondaryChange From Baseline in Lipids at Week 26

Lipid (total cholesterol, high density lipoprotein cholesterol \[HDL-c\], low density lipoprotein cholesterol \[LDL-c\], triglycerides) lab value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/dL
Change From Baseline in Lipids at Week 26
mg/dLInhaled Human InsulinInsulin Glargine
Total cholesterol, Week 26-2.80 ± 31.97-6.19 ± 29.95
HDL-c, Week 262.97 ± 6.990.69 ± 6.07
LDL-c, Week 26-2.09 ± 25.74-3.71 ± 23.63
Triglycerides, Week 26-42.65 ± 87.70-46.23 ± 147.8
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.0735 · Mean difference (final values): 5.21 · 95% CI -0.50 to 10.91
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.0017 · Mean difference (final values): 2.09 · 95% CI 0.79 to 3.39
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.1369 · Mean difference (final values): 3.43 · 95% CI -1.10 to 7.96
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.5684 · Mean difference (final values): 4.26 · 95% CI -10.40 to 18.92
SecondaryChange From Baseline in Cardiovascular (CV) Biomarkers High Sensitivity C-reactive Protein (Hs-CRP), Leptin, and Spot Urine Microalbumin at Week 26

CV biomarker (hs-CRP, Leptin, and Spot Urine Microalbumin) lab value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/L
Change From Baseline in Cardiovascular (CV) Biomarkers High Sensitivity C-reactive Protein (Hs-CRP), Leptin, and Spot Urine Microalbumin at Week 26
mg/LInhaled Human InsulinInsulin Glargine
hs-CRP, Week 260.61 ± 4.560.32 ± 3.69
Leptin, Week 263.68 ± 13.504.41 ± 10.50
Spot Urine Microalbumin, Week 263.47 ± 96.483.70 ± 54.53
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.5673 · Mean difference (final values): 0.24 · 95% CI -0.58 to 1.06
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.6099 · Mean difference (final values): -0.61 · 95% CI -2.97 to 1.75
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.7684 · Mean difference (final values): 2.28 · 95% CI -12.94 to 17.51
SecondaryChange From Baseline in CV Biomarkers Adiponectin and Apolipoprotein B (ApoB) at Week 26

CV biomarker (adiponectin and ApoB) lab value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/mL
Change From Baseline in CV Biomarkers Adiponectin and Apolipoprotein B (ApoB) at Week 26
mg/mLInhaled Human InsulinInsulin Glargine
Adiponectin, Week 260.23 ± 5.58-0.32 ± 5.15
ApoB, Week 26-0.06 ± 0.19-0.06 ± 0.17
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.5005 · Mean difference (final values): 0.36 · 95% CI -0.69 to 1.42
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.6850 · Mean difference (final values): 0.01 · 95% CI -0.03 to 0.04
SecondaryChange From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26

24-Hour CGMS glucose lab value was obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/dL
Change From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26
mg/dLInhaled Human InsulinInsulin Glargine
Change From Baseline in 24-Hour Continuous Glucose Monitoring System (CGMS) Glucose Values at Week 26-36.53 ± 33.96-35.63 ± 58.19
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.1856 · Mean difference (final values): 58.70 · 95% CI -43.37 to 160.77
SecondaryChange From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26

SD of 24-Hour CGMS glucose lab value obtained using the Medtronic MiniMed CGMS. Not all subjects were offered the opportunity to participate in this assessment. Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · mg/dL
Change From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26
mg/dLInhaled Human InsulinInsulin Glargine
Change From Baseline in Mean Standard Deviation (SD) of 24-Hour Glucose Values Measured by CGMS at Week 26-12.50 ± 2.554.46 ± 11.51
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.1862 · Mean difference (final values): -18.72 · 95% CI -51.34 to 13.89
SecondaryNumber of Subjects With Hypoglycemic Events

A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. An event was severe if the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.

Time frame:
Months 1 to 7
Reported as:
Number · participants
Number of Subjects With Hypoglycemic Events
participantsInhaled Human InsulinInsulin Glargine
Overall at Month 17024
Mild/Moderate at Month 16924
Severe at Month 100
Overall at Month 29838
Mild/Moderate at Month 29838
Severe at Month 210
Overall at Month 38435
Mild/Moderate at Month 38335
Severe at Month 330
Overall at Month 46125
Mild/Moderate at Month 46125
Severe at Month 400
Overall at Month 55530
Mild/Moderate at Month 55530
Severe at Month 500
Overall at Month 64231
Mild/Moderate at Month 64231
Severe at Month 600
Overall at Month 784
Mild/Moderate at Month 784
Severe at Month 700
SecondaryNumber of Total Hypoglycemic Events

A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe. Total=events during the study.

Time frame:
Months 1 to 7
Reported as:
Number · events
Number of Total Hypoglycemic Events
eventsInhaled Human InsulinInsulin Glargine
Overall at Month 119541
Mild/Moderate at Month 119441
Severe at Month 100
Overall at Month 236566
Mild/Moderate at Month 236466
Severe at Month 210
Overall at Month 329284
Mild/Moderate at Month 328984
Severe at Month 330
Overall at Month 416651
Mild/Moderate at Month 416651
Severe at Month 400
Overall at Month 515764
Mild/Moderate at Month 515764
Severe at Month 500
Overall at Month 611963
Mild/Moderate at Month 611963
Severe at Month 600
Overall at Month 7125
Mild/Moderate at Month 7125
Severe at Month 700
SecondaryNumber of Total Subject Months of Treatment

Number of total subject months of treatment. Subject months = number of days from start of treatment to the last day of active treatment + 1 day lag, including off-drug time)/30.44. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.

Time frame:
Months 1 to 7
Reported as:
Number · subject months
Number of Total Subject Months of Treatment
subject monthsInhaled Human InsulinInsulin Glargine
Overall at Month 1145.882.4
Mild/Moderate at Month 1145.882.4
Severe at Month 1145.882.4
Overall at Month 2138.381.0
Mild/Moderate at Month 2138.381.0
Severe at Month 2138.381.0
Overall at Month 3128.880.4
Mild/Moderate at Month 3128.880.4
Severe at Month 3128.880.4
Overall at Month 4117.779.7
Mild/Moderate at Month 4117.779.7
Severe at Month 4117.779.7
Overall at Month 5112.277.9
Mild/Moderate at Month 5112.277.9
Severe at Month 5112.277.9
Overall at Month 6103.575.7
Mild/Moderate at Month 6103.575.7
Severe at Month 6103.575.7
Overall at Month 712.86.6
Mild/Moderate at Month 712.86.6
Severe at Month 712.86.6
SecondaryCrude Hypoglycemic Event Rate

crude event rate=(events)/(subject-months). Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Overall=mild, moderate, and severe.

Time frame:
Months 1 to 7
Reported as:
Number · events / subject-months
Crude Hypoglycemic Event Rate
events / subject-monthsInhaled Human InsulinInsulin Glargine
Overall at Month 11.30.5
Mild/Moderate at Month 11.30.5
Severe at Month 100
Overall at Month 22.60.8
Mild/Moderate at Month 22.60.8
Severe at Month 20.70
Overall at Month 32.31.0
Mild/Moderate at Month 32.21.0
Severe at Month 32.30
Overall at Month 41.40.6
Mild/Moderate at Month 41.40.6
Severe at Month 400
Overall at Month 51.40.8
Mild/Moderate at Month 51.40.8
Severe at Month 500
Overall at Month 61.20.8
Mild/Moderate at Month 61.20.8
Severe at Month 600
Overall at Month 70.90.8
Mild/Moderate at Month 70.90.8
Severe at Month 700
SecondaryNumber of Nocturnal Hypoglycemic Events

A hypoglycemic event was identified by characteristic symptoms or blood glucose levels. Severe=the subject was unable to treat him/herself; had at least 1 neurological symptom; or blood glucose of \< = 49 mg/dL. Events not meeting all 3 criteria were considered mild-moderate. Nocturnal hypoglycemia=event occuring from midnight to 5:59 am.

Time frame:
Months 1 to 7
Reported as:
Number · events
Number of Nocturnal Hypoglycemic Events
eventsInhaled Human InsulinInsulin Glargine
Number of Nocturnal Hypoglycemic Events187114
SecondaryChange From Baseline in Body Weight at Week 26

Body weight value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · kg
Change From Baseline in Body Weight at Week 26
kgInhaled Human InsulinInsulin Glargine
Change From Baseline in Body Weight at Week 263.55 ± 4.742.33 ± 3.80
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.0055 · Mean difference (final values): 1.20 · 95% CI 0.35 to 2.04
SecondaryChange From Baseline in Body Mass Index (BMI) at Week 26

BMI value (kg/m2): Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · kg/m2
Change From Baseline in Body Mass Index (BMI) at Week 26
kg/m2Inhaled Human InsulinInsulin Glargine
Change From Baseline in Body Mass Index (BMI) at Week 261.22 ± 1.660.80 ± 1.30
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.0053 · Mean difference (final values): 0.42 · 95% CI 0.12 to 0.71
Other pre-specifiedChange From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS

HbA1c lab value: Change = value at Week 26 minus value at Baseline.

Time frame:
Baseline, Week 26
Reported as:
Mean · percent
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS
percentInhaled Human InsulinInsulin Glargine
Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the FAS-1.91 ± 1.41-1.67 ± 1.38
Statistical analysis
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = <0.0001 · Mean difference (final values): -0.27 · 95% CI -0.47 to -0.08A CI approach was presented with a two-sided 95% CI of the difference between treatment and control.
  • Inhaled Human Insulin vs Insulin Glargine · ANCOVA · p = 0.0062 · Mean difference (final values): -0.27 · 95% CI -0.47 to -0.08The superiority test used a one-sided 2.5% level of significance.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Human Insulin———
Insulin Glargine———
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventInhaled Human InsulinInsulin Glargine
PancreatitisGastrointestinal disorders2/2120/190
Angina pectorisCardiac disorders1/2121/190
Cardiovascular disorderCardiac disorders0/2121/190
SepsisInfections and infestations0/2121/190
Benign prostatic hyperplasiaReproductive system and breast disorders0/2121/190
Angina unstableCardiac disorders1/2120/190
PalpitationsCardiac disorders1/2120/190
Chest painGeneral disorders1/2120/190
Hepatitis AInfections and infestations1/2120/190
Ankle fractureInjury, poisoning and procedural complications1/2120/190
Most frequent other events
Showing 10 of 17
Most frequent other events
EventInhaled Human InsulinInsulin Glargine
HypoglycaemiaMetabolism and nutrition disorders144/21283/190
TremorNervous system disorders67/21243/190
DizzinessNervous system disorders40/21229/190
HyperhidrosisSkin and subcutaneous tissue disorders35/21221/190
Upper respiratory tract infectionInfections and infestations23/21229/190
HeadacheNervous system disorders29/21217/190
AstheniaGeneral disorders28/21217/190
NauseaGastrointestinal disorders21/21215/190
CoughRespiratory, thoracic and mediastinal disorders18/2126/190
Weight increasedInvestigations17/2129/190

Baseline characteristics

Age, Customized
Age, Customized(participants)Inhaled Human InsulinInsulin GlargineTotal
18 to 44 years272653
45 to 65 years151125276
>=65 years343973
Sex: Female, Male
Sex: Female, Male(Participants)Inhaled Human InsulinInsulin GlargineTotal
Female9284176
Male120106226
Gender
Gender(Participants)Inhaled Human InsulinInsulin GlargineTotal
Female9284176
Male120106226
08

Study locations

73 sites
  • Pfizer Investigational Site
    Phoenix, Arizona 85051, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712, United States
  • Pfizer Investigational Site
    Concord, California 94520, United States
  • Pfizer Investigational Site
    Encino, California 91436, United States
  • Pfizer Investigational Site
    Fresno, California 93720, United States
  • Pfizer Investigational Site
    Fullerton, California 92835, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Mission Viejo, California 92691, United States
  • Pfizer Investigational Site
    Pasadena, California 91105, United States
  • Pfizer Investigational Site
    San Diego, California 92120, United States
  • Pfizer Investigational Site
    San Diego, California 92128, United States
  • Pfizer Investigational Site
    San Luis Obispo, California 93401, United States
  • Pfizer Investigational Site
    Spring Valley, California 91978, United States
  • Pfizer Investigational Site
    Stockton, California 95204, United States
  • Pfizer Investigational Site
    Walnut Creek, California 94598, United States
  • Pfizer Investigational Site
    West Hills, California 91307, United States
  • Pfizer Investigational Site
    Golden, Colorado 80401, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Newark, Delaware 19713, United States
  • Pfizer Investigational Site
    Chiefland, Florida 32626, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33765, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33023, United States
  • Pfizer Investigational Site
    Kissimmee, Florida 34741, United States
  • Pfizer Investigational Site
    Miami, Florida 33156, United States
  • Pfizer Investigational Site
    Ocala, Florida 34471, United States
  • Pfizer Investigational Site
    Saint Cloud, Florida 34769, United States
  • Pfizer Investigational Site
    Winter Park, Florida 32789, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30322, United States
  • Pfizer Investigational Site
    Lawrenceville, Georgia 30045-3388, United States
  • Pfizer Investigational Site
    Lawrenceville, Georgia 30045, United States
  • Pfizer Investigational Site
    Woodstock, Georgia 30189, United States
  • Pfizer Investigational Site
    Boise, Idaho 83702, United States
  • Pfizer Investigational Site
    Hayden Lake, Idaho 83835, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46254, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66211, United States
  • Pfizer Investigational Site
    Topeka, Kansas 66606, United States
  • Pfizer Investigational Site
    Lexington, Kentucky 40503, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40213, United States
  • Pfizer Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70121, United States
  • Pfizer Investigational Site
    Haverhill, Massachusetts 01830-6141, United States
  • Pfizer Investigational Site
    Springfield, Missouri 65807, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68131, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89104, United States
  • Pfizer Investigational Site
    Staten Island, New York 10301, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28209-3734, United States
  • Pfizer Investigational Site
    Statesville, North Carolina 28625, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Kettering, Ohio 45429, United States
  • Pfizer Investigational Site
    Maumee, Ohio 43537-9402, United States
  • Pfizer Investigational Site
    Toledo, Ohio 43606, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • Pfizer Investigational Site
    Medford, Oregon 97504, United States
  • Pfizer Investigational Site
    Melrose Park, Pennsylvania 19027, United States
  • Pfizer Investigational Site
    Greenville, South Carolina 29615, United States
  • Pfizer Investigational Site
    Greer, South Carolina 29651, United States
  • Pfizer Investigational Site
    Spartanburg, South Carolina 29303, United States
  • Pfizer Investigational Site
    Milan, Tennessee 38358, United States
  • Pfizer Investigational Site
    Arlington, Texas 76014-2010, United States
  • Pfizer Investigational Site
    Beaumont, Texas 77701, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    Dallas, Texas 75231, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    El Paso, Texas 79935, United States
  • Pfizer Investigational Site
    Houston, Texas 77008, United States
  • Pfizer Investigational Site
    Houston, Texas 77083, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229-3900, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Bennington, Vermont 05201-5018, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23249, United States
  • Pfizer Investigational Site
    Federal Way, Washington 98003, United States
  • Pfizer Investigational Site
    Menomonee Falls, Wisconsin 53051, United States
  • Pfizer Investigational Site
    Carolina, 00983, Puerto Rico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2007
First posted
Jan 5, 2007
Start
Mar 2007
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Sep 4, 2009
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00418522
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 5, 2007
Start date
Mar 2007
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Sep 4, 2009
Last update
Aug 11, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion